Thrombosis in Pediatric Cardiac Patients

Paul Monagle

doi:10.1055/s-2004-815637

Seminars in Thrombosis and Hemostasis, Inhaltsverzeichnis

Semin Thromb Hemost 2003; 29(6): 547-556
DOI: 10.1055/s-2004-815637

Thrombosis in Pediatric Cardiac Patients

Paul Monagle

Associate Professor, Director, Division of Laboratory Services, Royal Children's Hospital, Department of Paediatrics, University of Melbourne, Melbourne, Victoria, Australia

Abstract

ABSTRACT

Cardiac disease and thrombosis are intimately related in adults, but primary myocardial infarction in children is rare. Homozygous familial hyperlipidemia occurs in approximately 1 million children, and causes severe coronary artery disease during childhood. Kawasaki's disease is an acquired inflammatory disorder, which, if untreated, leads to coronary artery aneurysms and subsequent myocardial infarction. The current understanding of the pathophysiology and management of these conditions is discussed. More commonly, the relationship between cardiac disease in children and thrombosis is that children being treated for congenital structural cardiac disease develop iatrogenic thrombosis, most commonly precipitated by central venous access. The epidemiology of common treatment-induced thrombosis is described, and management guidelines presented. Finally, many cardiac surgical procedures increase the risk of thrombosis, and prophylactic antithrombotic therapy is commonly used. The current evidence for prophylaxis in different clinical situations is presented. Additional study is required in all areas to improve the outcome for children affected by cardiac disease and thrombosis.

KEYWORDS

Children - thrombosis - myocardial infarction - congenital heart disease

Volltext

Referenzen

REFERENCES

1 Haber C, Kwiterovich Jr O P. Dyslipoproteinemia and xanthomatosis. Pediatr Dermatol . 1984; 1 261-280
2 West R J, Lloyd J K. Hypercholesterolemia in childhood. Adv Pediatr . 1979; 26 1-34
3 Fallat R W, Tsang R C, Glueck C J. Hypercholesterolemia and hypertriglyceridemia in children. Prev Med . 1974; 3 390-405
4 Haitas B, Baker S G, Meyer T E. et al . Natural history and cardiac manifestations of homozygous familial hypercholesterolaemia. Q J Med . 1990; 76 731-740
5 Rose V, Wilson G, Steiner G. Familial hypercholesterolemia: report of coronary death at age 3 in a homozygous child and prenatal diagnosis in a heterozygous sibling. J Pediatr . 1982; 100 757-759
6 Sprecher D L, Schaefer E J, Kent K M. et al . Cardiovascular features of homozygous familial hypercholesterolemia: analysis of 16 patients. Am J Cardiol . 1984; 54 20-30
7 Hoeg J M. Familial hypercholesterolemia. What the zebra can teach us about the horse. JAMA . 1994; 271 543-546
8 Goldstein J L, Brown M S. The LDL receptor defect in familial hypercholesterolemia. Implications for pathogenesis and therapy. Med Clin North Am . 1982; 66 335-362
9 Williams M L. Death of a child as a result of familial hypercholesterolaemia Med J Aust . 1989; 150 93-94
10 Clemens P, Beisiegel U, Steinhagen-Thiessen E. Family study in familial hypercholesterolemia with a receptor-negative homozygous 9-year-old boy. Helv Paediatr Acta . 1986; 41 173-182
11 Goldstein J, Brown M. Familial hyercholesterolemia. In: Stanbury JB, ed. Metabolic Basis of Inherited Disease, Chapter 33 New York: McGraw Hill 1989: 672-712
12 Leonard J V, Clarke M, Macartney F J. et al . Progression of atheroma in homozygous familial hypercholesterolaemia during regular plasma exchange (letter). Lancet . 1981; 2 811
13 Raper S E, Grossman M, Rader D J. et al . Safety and feasibility of liver-directed ex vivo gene therapy for homozygous familial hypercholesterolemia Ann Surg . 1996; 223 116-126
14 Celermajer D S, Sorensen K E, Gooch V M. et al . Non-invasive detection of endothelial dysfunction in children and adults at risk of atherosclerosis. Lancet . 1992; 340 1111-1115
15 Sorensen K E, Celermajer D S, Georgakopoulos D. et al . Impairment of endothelium-dependent dilation is an early event in children with familial hypercholesterolemia and is related to the lipoprotein(a) level. J Clin Invest . 1994; 93 50-55
16 Hegele R A, Connelly P W, Cullen-Dean G. et al . Elevated plasma lipoprotein(a) associated with abnormal stress thallium scans in children with familial hypercholesterolemia. Am J Cardiol . 1993; 72 402-406
17 Mouratidis B, Vaughan-Neil E F, Gilday D L. et al . Detection of silent coronary artery disease in adolescents and young adults with familial hypercholesterolemia by single-photon emission computed tomography thallium-201 scanning. Am J Cardiol . 1992; 70 1109-1112
18 Rubinsztein D C, Raal F J, Seftel H C. et al . Characterization of six patients who are double heterozygotes for familial hypercholesterolemia and familial defective apo B-100. Arterioscler Thromb . 1993; 13 1076-1081
19 Rauh G, Keller C, Kormann B. et al . Familial defective apolipoprotein B100: clinical characteristics of 54 cases. Atherosclerosis . 1992; 92 233-241
20 Salen G, Horak I, Rothkopf M. et al . Lethal atherosclerosis associated with abnormal plasma and tissue sterol composition in sitosterolemia with xanthomatosis. J Lipid Res . 1985; 26 1126-1133
21 Kawasaki T. Discovery of Kawasaki disease (muco-cutaneous lymph node syndrome) and its research activities. Nippon Rinsho . 1976; 34 222-227
22 Durongpisitkul K, Gururaj V J, Park J M. et al . The prevention of coronary artery aneurysm in Kawasaki disease: a meta-analysis on the efficacy of aspirin and immunoglobulin treatment. Pediatrics . 1995; 96 1057-1061
23 Furusho K, Kamiya T, Nakano H. et al . High-dose intravenous gammaglobulin for Kawasaki disease. Lancet . 1984; 2 1055-1058
24 Newburger J W, Takahashi M, Burns J C. et al . The treatment of Kawasaki syndrome with intravenous gamma globulin. N Engl J Med . 1986; 315 341-347
25 Newburger J W, Takahashi M, Beiser A S. et al . A single intravenous infusion of gamma globulin as compared with four infusions in the treatment of acute Kawasaki syndrome. N Engl J Med . 1991; 324 1633-1639
26 Koren G, Rose V, Lavi S. et al . Probable efficacy of high-dose salicylates in reducing coronary involvement in Kawasaki disease. JAMA . 1985; 254 767-769
27 Daniels S R, Specker B, Capannari T E. et al . Correlates of coronary artery aneurysm formation in patients with Kawasaki disease. Am J Dis Child . 1987; 141 205-207
28 Williams R V, Wilke V M, Tani L Y. et al . Does abciximab enhance regression of coronary aneurysms resulting from Kawasaki disease?. Pediatrics . 2002; 109 E4
29 Suzuki A, Kamiya T, Ono Y. et al . Myocardial ischemia in Kawasaki disease: follow-up study by cardiac catheterization and coronary angiography. Pediatr Cardiol . 1988; 9 1-5
30 Kato H, Sugimura T, Akagi T. et al . Long-term consequences of Kawasaki disease. A 10- to 21-year follow-up study of 594 patients. Circulation . 1996; 94 1379-1385
31 Gersony W M. Diagnosis and management of Kawasaki disease. JAMA . 1991; 265 2699-2703
32 Tatara K, Kusakawa S. Long-term prognosis of giant coronary aneurysm in Kawasaki disease: an angiographic study. J Pediatr . 1987; 111 705-710
33 The GUSTO Angiographic Investigators. The effects of tissue plasminogen activator, streptokinase, or both on coronary-artery patency, ventricular function, and survival after acute myocardial infarction. N Engl J Med . 1993; 329 1615-1622
34 Kitamura S, Kameda Y, Kawashima Y. Surgery for Kawasaki disease. Adv Card Surg . 1997; 9 177-194
35 Smith C, Green R M. Pediatric vascular injuries. Surgery . 1981; 90 20-31
36 Perry M O. Iatrogenic injuries of arteries in infants. Surg Gynecol Obstet . 1983; 157 415-418
37 Burrows P E, Benson L N, Williams W G. et al . Iliofemoral arterial complications of balloon angioplasty for systemic obstructions in infants and children. Circulation . 1990; 82 1697-1704
38 Mortensson W, Hallbook T, Lundstrom N R. Percutaneous catheterization of the femoral vessels in children. II. Thrombotic occlusion of the catheterized artery: frequency and causes. Pediatr Radiol . 1975; 4 1-9
39 Mortensson W. Angiography of the femoral artery following percutaneous catheterization in infants and children. Acta Radiol . 1976; 17 581-593
40 Padmanabhan J, Krovetz L J, Varghese P J. et al . Effect of topical papaverine in preventing thrombosis following arteriotomies. A double-blind study in infants and children. J Pediatr . 1972; 81 792-793
41 Freed M D, Keane J F, Rosenthal A. The use of heparinization to prevent arterial thrombosis after percutaneous cardiac catheterization in children. Circulation . 1974; 50 565-569
42 Ino T, Benson L N, Freedom R M. et al . Thrombolytic therapy for femoral artery thrombosis after pediatric cardiac catheterization. Am Heart J . 1988; 115 633-639
43 Rao P S, Thapar M K, Rogers Jr H J. et al . Effect of intraarterial injection of heparin on the complications of percutaneous arterial catheterization in infants and children. Cathet Cardiovasc Diagn . 1981; 7 235-246
44 Butt W, Shann F, McDonnell G. et al . Effect of heparin concentration and infusion rate on the patency of arterial catheters. Crit Care Med . 1987; 15 230-232
45 Saxena A, Gupta R, Kumar R K. et al . Predictors of arterial thrombosis after diagnostic cardiac catheterization in infants and children randomized to two heparin dosages. Cathet Cardiovasc Diagn . 1997; 41 400-403
46 McFadden P M, Ochsner J L, Mills N. Management of thrombotic complications of invasive arterial monitoring of the upper extremity. J Cardiovasc Surg (Torino) . 1983; 24 35-39
47 Vlad P, Hohn A, Lambert E C. Retrograde arterial catheterization of the left heart. Experience with 500 infants and children. Circulation . 1964; 29 787-793
48 Jones J, Hunter D. Consensus methods for medical and health services research. BMJ . 1995; 311 376-380
49 Stanger P, Heymann M A, Tarnoff H. et al . Complications of cardiac catheterization of neonates, infants, and children. A three-year study. Circulation . 1974; 50 595-608
50 Hurwitz R A, Franken Jr A E, Girod D A. et al . Angiographic determination of arterial patency after percutaneous catheterization in infants and small children. Circulation . 1977; 56 102-105
51 Girod D A, Hurwitz R A, Caldwell R L. Heparinization for prevention of thrombosis following pediatric percutaneous arterial catheterization. Pediatr Cardiol . 1982; 3 175-180
52 Wessel D L, Keane J F, Fellows K E. et al . Fibrinolytic therapy for femoral arterial thrombosis after cardiac catheterization in infants and children. Am J Cardiol . 1986; 58 347-351
53 Gagnon R M, Goudreau E, Joyal F. et al . The role of intravenous streptokinase in acute arterial occlusions after cardiac catheterization. Cathet Cardiovasc Diagn . 1985; 11 409-412
54 Zenz W, Muntean W, Beitzke A. et al . Tissue plasminogen activator (alteplase) treatment for femoral artery thrombosis after cardiac catheterisation in infants and children. Br Heart J . 1993; 70 382-385
55 Brus F, Witsenburg M, Hofhuis W J. et al . Streptokinase treatment for femoral artery thrombosis after arterial cardiac catheterisation in infants and children. Br Heart J . 1990; 63 291-294
56 Kothari S S, Kumar R K, Varma S. et al . Thrombolytic therapy in infants for femoral artery thrombosis following cardiac catheterisation. Indian Heart J . 1996; 48 246-248
57 Freed M D, Rosenthal A, Fyler D. Attempts to reduce arterial thrombosis after cardiac catheterization in children: use of percutaneous technique and aspirin. Am Heart J . 1974; 87 283-286
58 Kern I B. Management of children with chronic femoral artery obstruction. J Pediatr Surg . 1977; 12 83-90
59 Taylor Jr M L, Troutman R, Feliciano P. et al . Late complications after femoral artery catheterization in children less than five years of age. J Vasc Surg . 1990; 11 297-304
60 Celermajer D S, Robinson J T, Taylor J F. Vascular access in previously catheterised children and adolescents: a prospective study of 131 consecutive cases. Br Heart J . 1993; 70 554-557
61 Taussig H B. Long-time observations on the Blalock-Taussig operation IX. Single ventricle (with apex to the left). Johns Hopkins Med J . 1976; 139 69-76
62 Truccone N J, Bowman Jr O F, Malm J R. et al . Systemic-pulmonary arterial shunts in the first year of life. Circulation . 1974; 49 508-511
63 Godart F, Qureshi S A, Simha A. et al . Effects of modified and classic Blalock-Taussig shunts on the pulmonary arterial tree. Ann Thorac Surg . 1998; 66 512-517
64 Tsai K T, Chang C H, Lin P J. Modified Blalock-Taussig shunt: statistical analysis of potential factors influencing shunt outcome. J Cardiovasc Surg (Torino) . 1996; 37 149-152
65 Gladman G, McCrindle B W, Williams W G. et al . The modified Blalock-Taussig shunt: clinical impact and morbidity in Fallot's tetralogy in the current era. J Thorac Cardiovasc Surg . 1997; 114 25-30
66 Bogats G, Kertesz E, Katona M. et al . Modified Blalock-Taussig shunt using allograft saphenous vein: six years' experience. Ann Thorac Surg . 1996; 61 58-62
67 Ohuchi H, Okabe H, Nagata N. et al . Long-term patency after the Blalock-Taussig operation-comparison between classic and modified shunts. Nippon Kyobu Geka Gakkai Zasshi . 1996; 44 1108-1113
68 Zahn E M, Chang A C, Aldousany A. et al . Emergent stent placement for acute Blalock-Taussig shunt obstruction after stage 1 Norwood surgery. Cathet Cardiovasc Diagn . 1997; 42 191-194
69 Takanashi Y, Tomizawa Y, Noishiki Y. et al . Calcified EPTFE vascular prosthesis in the Blalock-Taussig shunt after 4 years of implantation: a case report. Kyobu Geka . 1997; 50 71-73
70 Berger R M, Bol-Raap G, Hop W J. et al . Heparin as a risk factor for perigraft seroma complicating the modified Blalock-Taussig shunt. J Thorac Cardiovasc Surg . 1998; 116 286-292
71 Klinge J, Hofbeck M, Ries M. et al . Thrombolysis of modified Blalock-Taussig shunts in childhood with recombinant tissue-type plasminogen activator. Z Kardiol . 1995; 84 476-480
72 Alcibar J, Cabrera A, Onate A. et al . Angioplasty of the stenotic Blalock-Taussig. Rev Esp Cardiol . 1994; 47 819-823
73 Ries M, Singer H, Hofbeck M. Thrombolysis of a modified Blalock-Taussig shunt with recombinant tissue plasminogen activator in a newborn infant with pulmonary atresia and ventricular septal defect. Br Heart J . 1994; 72 201-202
74 Boulden T F, Tonkin I L, Burton E M. et al . Case of the day. Pediatric. Mycotic pseudoaneurysm and thrombosis of modified left Blalock-Taussig shunt. Radiographics . 1990; 10 119-121
75 Ahmadi A, Mocellin R, Henglein D. et al . Modified Blalock-Taussig anostomosis. Its significance within the scope of surgical treatment of Tetralogy of Fallot. Monatsschr Kinderheilkd . 1988; 136 130-134
76 Brandt B, Camacho J A, Mahoney L T. et al . Growth of the pulmonary arteries following Blalock-Taussig shunt. Ann Thorac Surg . 1986; 42 S1-S4
77 Tamisier D, Vouhe P R, Vernant F. et al . Modified Blalock-Taussig shunts: results in infants less than 3 months of age. Ann Thorac Surg . 1990; 49 797-801
78 Mullen J C, Lemermeyer G, Bentley M J. Modified Blalock-Taussig shunts: to heparinize or not to heparinize?. Can J Cardiol . 1996; 12 645-647
79 Rajani R M, Dalvi B V, Kulkarni H L. et al . Acutely blocked Blalock-Taussig shunt following cardiac catheterization: successful recanalization with intravenous streptokinase. Am Heart J . 1990; 120 1238-1239
80 Hijazi Z M. Stenting for postoperative congenital heart disease in infants. Cathet Cardiovasc Diagn . 1997; 42 195-198
81 Monagle P, Cochrane A, McCrindle B. et al . Thromboembolic complications after Fontan procedures-the role of prophylactic anticoagulation. J Thorac Cardiovasc Surg . 1998; 115 493-498
82 Zahn E M, Lima V C, Benson L N. et al . Use of endovascular stents to increase pulmonary blood flow in pulmonary atresia with ventricular septal defect. Am J Cardiol . 1992; 70 411-412
83 Sade R, Ballenger J F, Hohn A. et al . Cardiac valve replacement in children: Comparison of tissue with mechanical prostheses. J Thorac Cardiovasc Surg . 1979; 78 123-127
84 Brown J W, Dunn J M, Spooner E. et al . Late spontaneous disruption of a porcine xenograft mitral valve. Clinical, hemodynamic, echocardiographic, and pathological findings. J Thorac Cardiovasc Surg . 1978; 75 606-611
85 Geha A S, Laks H, Stansel Jr C H. et al . Late failure of porcine valve heterografts in children. J Thorac Cardiovasc Surg . 1979; 78 351-364
86 Silver M M, Pollock J, Silver M D. et al . Calcification in porcine xenograft valves in children. Am J Cardiol . 1980; 45 685-689
87 Dunn J M. Porcine valve durability in children. Ann Thorac Surg . 1981; 32 357-368
88 Williams W G, Pollack J C, Geiss D M. et al . Experience with aortic and mitral valve replacement in children. J Thorac Cardiovasc Surg . 1981; 81 326-333
89 Miller D, Stinson E, Oyer P. et al . The durability of porcine xenograft valves and conduits in children. Circulation . 1982; 66(suppl I, Pt 2) I172-I185
90 Odell J. Calcification of porcine bioprostheses in children. In: Cohn L, Gallucci V, eds. Cardiac Bioprostheses: Proceedings of the Second International Symposium New York: Yorke Medical Books 1982: 231
91 Williams D B, Danielson G K, McGoon D C. et al . Porcine heterograft valve replacement in children. J Thorac Cardiovasc Surg . 1982; 84 446-450
92 Champsaur G, Robin J, Tronc F. et al . Mechanical valve in aortic position is a valid option in children and adolescents. Eur J Cardiothorac Surg . 1997; 11 117-122
93 Yankah A C, Alexi-Meskhishvili V, Weng Y. et al . Performance of aortic and pulmonary homografts in the right ventricular outflow tract in children. J Heart Valve Dis . 1995; 4 392-395
94 Monagle P, Michelson A D, Bovill E. et al . Antithrombotic therapy in children. Chest . 2001; 119 344S-370S